X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (38) 38
eliglustat (37) 37
humans (31) 31
enzyme replacement therapy (30) 30
gaucher disease (26) 26
substrate reduction therapy (23) 23
eliglustat tartrate (19) 19
gaucher disease - drug therapy (18) 18
imiglucerase (17) 17
enzyme inhibitors - therapeutic use (16) 16
genetics & heredity (16) 16
animals (15) 15
glucocerebrosidase (13) 13
pyrrolidines - therapeutic use (13) 13
medicine, research & experimental (12) 12
enzymes (11) 11
female (10) 10
gaucher's disease (10) 10
glucosylceramide synthase (10) 10
male (10) 10
adults (9) 9
gaucher disease type 1 (9) 9
miglustat (9) 9
open-label (9) 9
reduction (9) 9
adult (8) 8
glucosyltransferases - antagonists & inhibitors (8) 8
medicine (8) 8
mice (8) 8
type-1 (8) 8
biochemistry & molecular biology (7) 7
diagnosis (7) 7
drug therapy (7) 7
endocrinology & metabolism (7) 7
gaucher-disease (7) 7
genetics (7) 7
lipids (7) 7
pharmacology & pharmacy (7) 7
treatment outcome (7) 7
trial (7) 7
analysis (6) 6
clinical trials (6) 6
eliglustat tartrate genz-112638 (6) 6
gaucher disease - enzymology (6) 6
glucosylceramide (6) 6
hematology (6) 6
lysosomal storage disease (6) 6
mutation (6) 6
n-butyldeoxynojirimycin (6) 6
research (6) 6
therapy (6) 6
article (5) 5
disease (5) 5
gaucher disease - genetics (5) 5
gaucher disease - pathology (5) 5
glucosylceramidase - therapeutic use (5) 5
glycosphingolipids (5) 5
manifestations (5) 5
medical research (5) 5
medicine, general & internal (5) 5
middle aged (5) 5
molecular biology (5) 5
non-inferiority (5) 5
oral eliglustat (5) 5
phenotype (5) 5
recommendations (5) 5
review (5) 5
safety (5) 5
acid beta-glucosidase (4) 4
acid β-glucosidase deficiency (4) 4
anemia (4) 4
biomarkers (4) 4
case-control studies (4) 4
cell biology (4) 4
deficiency (4) 4
drug interactions (4) 4
drug metabolism (4) 4
enzyme inhibitors - pharmacology (4) 4
enzyme replacement (4) 4
fabry-disease (4) 4
gaucher disease - metabolism (4) 4
genotype (4) 4
glucosylceramides - metabolism (4) 4
glucosyltransferases - metabolism (4) 4
health aspects (4) 4
internal medicine (4) 4
lysosomal storage disorder (4) 4
medicine, experimental (4) 4
metabolism (4) 4
phase-3 (4) 4
physiological aspects (4) 4
platelet count (4) 4
type-1 gaucher-disease (4) 4
1-deoxynojirimycin - analogs & derivatives (3) 3
1-deoxynojirimycin - therapeutic use (3) 3
administration, oral (3) 3
adolescent (3) 3
biochemistry (3) 3
biology (3) 3
biosynthesis (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of Pharmaceutical and Biomedical Analysis, ISSN 0731-7085, 01/2020, Volume 177, p. 112858
Eliglustat is an oral substrate reduction therapy drug and has been approved as a first-line treatment for adults with Gaucher disease type 1 (GD 1). In the... 
UPLC-MS/MS | Eliglustat | Method | Pharmacokinetics | Rat plasma
Journal Article
Journal Article
Organic Process Research and Development, ISSN 1083-6160, 06/2019, Volume 23, Issue 6, pp. 1204 - 1212
An efficient and scalable synthesis of eliglustat (1) is herein reported. This novel route features a three-step telescoped process to afford the... 
asymmetric transfer hydrogenation | asymmetric synthesis | ruthenium catalyst | eliglustat | dynamic kinetic resolution | CHEMISTRY, ORGANIC | CHEMISTRY, APPLIED
Journal Article
Journal of pathology, ISSN 0022-3417, 2015, Volume 235, Issue 1, pp. 113 - 124
Journal Article
Yakugaku Zasshi, ISSN 0031-6903, 2018, Volume 138, Issue 3, pp. 365 - 371
Journal Article
Blood Cells, Molecules and Diseases, ISSN 1079-9796, 12/2014, Volume 53, Issue 4, pp. 274 - 276
Eliglustat is an investigational, oral substrate reduction therapy for Gaucher disease type 1 (GD1). Nineteen treatment-naïve patients have now completed 4... 
Acid β-glucosidase deficiency | Gaucher disease type 1 | Eliglustat | Substrate reduction therapy | Clinical trials | Hemoglobin
Journal Article
European Journal of Internal Medicine, ISSN 0953-6205, 2016, Volume 37, pp. 25 - 32
Journal Article
Journal Article
Therapeutics and Clinical Risk Management, ISSN 1176-6336, 01/2016, Volume 12, pp. 53 - 58
Journal Article
BBA - Molecular and Cell Biology of Lipids, ISSN 1388-1981, 04/2016, Volume 1861, Issue 4, pp. 269 - 284
Journal Article
Journal of research in pharmacy practice, ISSN 2319-9644, 10/2018, Volume 7, Issue 4, pp. 171 - 177
Gaucher's disease (GD) is one of the most common lysosomal diseases in humans. It results from β-glucosidase deficiency and leads to necrosis, especially in... 
Imiglucerase | Gaucher disease | Review | Eliglustat
Journal Article
YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, ISSN 0031-6903, 03/2018, Volume 138, Issue 3, pp. 365 - 371
Elderly patients often suffer from a variety of diseases and therefore may be prescribed several kinds of drugs. Interactions between these drugs may cause... 
CYP2C9 | drug interactions | flurbiprofen | eliglustat | GENOTYPE | drug metabolism | PHARMACOLOGY & PHARMACY | CYP | genetic polymorphism
Journal Article
Molecular Genetics and Metabolism Reports, ISSN 2214-4269, 12/2016, Volume 9, pp. 25 - 28
Gaucher disease type 1 is an autosomal recessive disorder caused by deficient activity of the lysosomal enzyme acid β-glucosidase resulting in accumulation of... 
Imiglucerase | Gaucher disease type 1 | Eliglustat | Velaglucerase alfa | Composite endpoint | Non-inferiority trial | EFFICACY | TARTRATE | SAFETY | OPEN-LABEL | PHASE-2 | NON-INFERIORITY | THERAPY | GENETICS & HEREDITY | ORAL ELIGLUSTAT
Journal Article
THERAPEUTICS AND CLINICAL RISK MANAGEMENT, ISSN 1178-203X, 2016, Volume 12, Issue Issue 1, pp. 53 - 58
Journal Article
Synthetic Communications, ISSN 0039-7911, 03/2018, Volume 48, Issue 5, pp. 594 - 600
Eliglustat, a ceramide glucosyltransferase inhibitor, was synthesized in six steps with 28.4% overall yield. The key features include the use of a... 
Aldol reaction | selective sulfonylation | eliglustat | stereogenic centers | ACID | CHIRAL AUXILIARIES | CHEMISTRY, ORGANIC | ALPHA | TYPE-1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITOR | GAUCHER-DISEASE
Journal Article
Blood Cells, Molecules and Diseases, ISSN 1079-9796, 02/2018, Volume 68, pp. 185 - 191
Eliglustat, an oral substrate reduction therapy, is a first-line therapy for adults with Gaucher disease type 1 and a compatible CYP2D6 metabolizer phenotype.... 
Acid β-glucosidase deficiency | Gaucher disease type 1 | Eliglustat | Safety | Adverse events | Substrate reduction therapy | DIAGNOSIS | REDUCTION | TARTRATE | PHENOTYPE | HEMATOLOGY | Acid beta-glucosidase deficiency | ENZYME REPLACEMENT THERAPY | Diarrhea | Clinical trials | Complications and side effects | Adults | Backache | Cytochrome P-450
Journal Article